Diagnosed with SMM, SPB, or MGUS?
Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
Category Archives for Pre-Myeloma
Smoldering Multiple Myeloma (SMM) – Chemo now, later?
“New studies (pre-habilitation) suggest that a multimodal approach that incorporates both physical and psychological prehabilitation interventions may be more effective than a unimodal approach that
Continue readingPre- Myeloma? Stage 1 Multiple Myeloma? Cure vs. Control
Should we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality
Continue readingRisk of Progression for Smoldering Multiple Myeloma is Reduced…at what cost?
“Lenalidomide (Revlimid) induced a 72% reduction in the risk of progression to symptomatic disease in patients with smoldering multiple myeloma at 3 years” The challenge with pre-myeloma, Monoclonal
Continue readingMultiple Myeloma Diet- Liver Enzymes, Inflammation
Regarding your question about multiple myeloma diet and liver enzymes, or I should say, a diet to bring down liver enzymes when they are high, I have linked an article below… Hello David, thank you
Continue readingRheumatologic Disease Inc. Risk of MGUS to Multiple Myeloma
“Patients with monoclonal gammopathy of undetermined significance (MGUS) have twice the risk of developing multiple myeloma (MM) if they have non-antibody (Ab)-mediated rheumatic diseases (RDs)…” Rheumatic
Continue readingMGUS, Myeloma AL Amyloidosis- Conventional, Non-Conventional
“Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement…in multiple myeloma or MGUS patients?” You’ve been diagnosed with multiple myeloma
Continue readingChemo for High Risk Smoldering Myeloma- Pain…
“…among the lenalidomide-treated patients, grade 3 or 4 hematologic and nonhematologic adverse events occurred in 36 patients (41%), with nonhematologic adverse events occurring in 25 patients
Continue readingMGUS, SMM- Cytogenetic Risk, TTP of Multiple Myeloma
“What determines the risk of progression from asymptomatic to symptomatic myeloma…Most widespread and validated adversely predictive chromosomal aberrations (high-risk aberrations) in this
Continue readingSolitary Plasmacytoma of Bone-
“Our study confirms that WBMRI detects skeletal disease in a higher number of treatment-naïve patients than 18F-FDG PET/CT and also detects a higher number of lesions per patient with concordance
Continue readingSMM, Stage 1 Myeloma- NOT SOC, Longer Prognosis
Standard-risk patients should never be undertreated, as they derive the highest relative benefit from using the best available registered therapies. (Oncology and I disagree…) Hi David – I
Continue reading